Article Information
History
- July 11, 2023.
Article Versions
- Version 1 (March 17, 2023 - 15:18).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Dr Anastasia Chatzilena, PhD1,†,
- Dr Catherine Hyams, PhD2,†,
- Dr Rob Challen, PhD3,
- Dr Robin Marlow, PhD4,
- Ms Jade King, MSc5,
- Mr David Adegbite, BSc6,
- Ms Jane Kinney, BSc7,
- Ms Madeleine Clout, BSc8,
- Prof Nick Maskell, MD9,
- Dr Jennifer Oliver, PhD10,
- Professor Adam Finn, PhD11,
- Dr Leon Danon, PhD12,*,
- The Avon CAP Research Group
- 1Engineering Mathematics, University of Bristol, Bristol, UK
- 2Population Health Sciences, University of Bristol, Bristol, UK
- 3Engineering Mathematics, University of Bristol, Bristol, UK
- 4Population Health Sciences, University of Bristol, Bristol, UK
- 5Clinical Research and Imaging Centre, UHBW NHS Trust, Bristol, UK
- 6Bristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, UK
- 7Bristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, UK
- 8Bristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, UK
- 9Academic Respiratory Unit, University of Bristol, Southmead Hospital, Bristol, UK
- 10Bristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, UK
- 11Bristol Vaccine Centre, Cellular and Molecular Medicine and Population Health Sciences, University of Bristol, Bristol, UK
- 12Engineering Mathematics, University of Bristol, Bristol, UK
- ↵*Corresponding Author: Leon Danon, PhD, Engineering Mathematics, University of Bristol, University Walk, Bristol BS8 1TW, United Kingdom, +44(0)117 455 7828, l.danon{at}bristol.ac.uk
↵† These authors contributed equally, and should be considered co-first or last authors
Posted July 11, 2023.
Relative vaccine effectiveness (rVE) of mRNA COVID-19 boosters in people aged at least 75 years in the UK vaccination programme, during the Spring-Summer (monovalent vaccine) and Autumn-Winter 2022 (bivalent vaccine) booster campaigns: a prospective test negative case-control study
